In a previous work performed in primary cutaneous melanoma samples, the authors described RAC3 as a prognostic marker for the prediction of survival associated with melanoma [46], while in breast cancer the RAC3 overexpression was considered as a predictor of resistance to Tamoxifen treatment [44]. The gene discussed is RAC3; the disease is cutaneous melanoma.